CIHR joins new initiative to accelerate progress against cancer worldwide
Message from the CIHR President and Scientific Director of the CIHR Institute of Cancer Research
May 9, 2023
Cancer is a leading cause of death, with 10 million individuals succumbing to this disease annually worldwide. One of the best strategies to accelerate progress is through international collaboration. The Canadian Institutes of Health Research and CIHR's Institute of Cancer Research are therefore pleased to be among the founding members of G7 Cancer (in French only), led by the French Institut national du cancer. This new alliance aims to further strengthen cooperation among cancer research funders around the world to address this major health challenge.
In signing on to G7 Cancer, CIHR is signaling its willingness to share knowledge and expertise with the other signatories, explore the development of new initiatives while leveraging existing ones, and prioritize international cooperation in cancer research.
CIHR has 40 international initiatives currently supported by bilateral and multilateral agreements that span multiple countries around the world. Canada has much to learn from our international peers, just as the global scientific community has much to learn from the insights and expertise of Canada's health researchers.
We believe that through the worldwide sharing of knowledge, G7 Cancer holds enormous promise to advance cancer prevention, detection, diagnosis, treatment, and improve the quality of life of cancer patients and survivors. Through the G7 Cancer partnership, CIHR will continue to explore opportunities to collaborate on cancer research to improve outcomes for cancer patients here in Canada and around the world.
Michael J. Strong, MD, FRCPC, FAAN, FCAHS
Fei-Fei Liu, MD, FRCPC, FASTRO, FCAHS
Scientific Director, CIHR Institute of Cancer Research
- Date modified: